• TCAIM-Mediated OGDH Regulation: A Novel Mitochondrial Contro

  2026-05-13

  Wang et al. (2025) reveal that the mitochondrial DNAJC co-chaperone TCAIM reduces a-ketoglutarate dehydrogenase (OGDH) protein levels, suppressing its activity and altering mitochondrial metabolism. This work uncovers an atypical post-translational regulatory mechanism, expanding current understanding of mitochondrial proteostasis and metabolic control.

• AI-Derived Prognostic Signature Advances HCC Risk Prediction

  2026-05-13

  This study introduces a consensus artificial intelligence-driven prognostic signature (CAIPS) for hepatocellular carcinoma (HCC) by integrating multiple machine learning algorithms across large, multi-center cohorts. CAIPS outperforms existing models in risk stratification, identifies actionable biomarkers and therapy candidates, and offers mechanistic insights for precision oncology.

• Peripheral RIPK1 and IL-8 as ALS Biomarkers: Primidone Repur

  2026-05-12

  This study demonstrates that elevated peripheral levels of RIPK1 and IL-8 serve as clinically relevant biomarkers for amyotrophic lateral sclerosis (ALS). The authors provide translational evidence that repurposing Primidone, a known antiepileptic, for RIPK1 inhibition reduces these biomarkers and delays ALS progression, offering new avenues for patient stratification and therapeutic intervention.

• Cefodizime: Advanced Workflows for Microbiology Research Suc

  2026-05-12

  Cefodizime, a third-generation cephalosporin antibiotic from APExBIO, delivers robust, β-lactamase-stable activity and immunomodulation for precise respiratory and urinary tract infection modeling. This guide translates recent resistance surveillance and experimental best practices into actionable protocols, troubleshooting, and optimized assay design.

• Faropenem Sodium: Transport, Mechanism, and Research Frontie

  2026-05-11

  Explore Faropenem sodium’s unique transport and inhibitory mechanisms as a penem antibiotic, integrating novel transporter insights for advanced research applications. Uncover what sets this molecule apart from other β-lactams.

• Applied Workflows with Cefodizime: Third-Generation Cephalos

  2026-05-11

  Cefodizime, a third-generation cephalosporin antibiotic, offers robust, β-lactamase-stable activity and unique immunomodulatory benefits for experimental microbiology. This guide translates reference-backed research into actionable workflows, troubleshooting strategies, and optimized assay parameters for infection modeling and resistance studies.

• Sodium Dicloxacillin Monohydrate: Precision for MSSA Researc

  2026-05-10

  This thought-leadership article explores sodium dicloxacillin monohydrate's mechanistic, experimental, and translational value in Gram-positive bacterial infection research, focusing on MSSA. By integrating quantitative insights, protocol guidance, and a strategic outlook, it provides translational researchers with actionable intelligence for optimizing preclinical workflows and anticipating future challenges in the field.

• Novobiocin: Applied Workflows and Troubleshooting in Antimic

  2026-05-09

  Novobiocin, an aminocoumarin antibiotic, offers distinct advantages for antibacterial, antiparasitic, and antiviral workflows due to its dual mechanism of action and robust efficacy profile. This article translates recent structural and biological findings into optimized protocols, troubleshooting guidance, and strategic use-cases for resistance and apoptosis research.

• Cisapride (R 51619): Transforming Cardiac Electrophysiology

  2026-05-09

  Cisapride (R 51619) is redefining predictive cardiac electrophysiology and cardiotoxicity profiling thanks to its dual action as a nonselective 5-HT4 receptor agonist and potent hERG channel inhibitor. Leveraging high-content screening with iPSC-derived cardiomyocytes and deep learning, researchers can now detect arrhythmogenic liabilities earlier and with greater precision.

• In Vitro Activity and Tissue Penetration of Temafloxacin: A

  2026-05-08

  This article reviews a pivotal study on temafloxacin, a fluoroquinolone broad-spectrum antibacterial agent, highlighting its comparative activity against 579 bacterial strains and its pharmacokinetic and tissue penetration profile in humans. The findings demonstrate temafloxacin’s potent activity against a range of Gram-positive and Gram-negative pathogens, strong tissue penetration, and support for once or twice daily dosing in research and clinical contexts.

• Verapamil HCl (SKU B1867): Resolving Lab Uncertainties in Ce

  2026-05-07

  This scenario-driven guide addresses core laboratory challenges in cell viability, proliferation, and cytotoxicity assays using Verapamil HCl (SKU B1867). Integrating recent literature and validated protocols, it demonstrates how this L-type calcium channel blocker from APExBIO delivers reproducibility and mechanistic clarity for myeloma, osteoporosis, and inflammation models.

• DMH-1: Selective ALK2 Inhibitor for Precision BMP Pathway Co

  2026-05-07

  DMH-1 is a potent, selective ALK2 inhibitor used to modulate BMP signaling in organoid and non-small cell lung cancer research. It achieves nanomolar potency, exclusive BMP pathway specificity, and reliable downstream inhibition of Smad1/5/8 phosphorylation and Id gene expression.

• Letrozole (SKU A1307): Reliable Aromatase Inhibition for Bre

  2026-05-06

  This article provides scenario-driven, evidence-based guidance for laboratory scientists utilizing Letrozole (SKU A1307), a potent non-steroidal aromatase inhibitor from APExBIO. It addresses common experimental challenges in cell viability and hormone-dependent cancer research, offering actionable insights and quantitative protocol benchmarks to enhance reproducibility and data integrity.

• Rapamycin (Sirolimus): Data-Driven mTOR Inhibition for Relia

  2026-05-06

  This article addresses practical laboratory challenges in cell viability and proliferation assays using Rapamycin (Sirolimus, SKU A8167). By blending real-world scenarios with evidence-based responses, we highlight how this specific mTOR inhibitor enables reproducible, sensitive, and interpretable results for researchers in cancer biology, immunology, and mitochondrial disease modeling.

• Cy5 Maleimide (Non-sulfonated): Protocols for Protein Labeli

  2026-05-05

  Cy5 maleimide (non-sulfonated) enables selective, site-specific fluorescent labeling of proteins and peptides via cysteine residues, supporting high-contrast detection in imaging and assay workflows. It is optimal for protocols requiring red-shifted fluorescence and robust thiol specificity, but not suitable when biomolecules lack accessible thiols or when organic solvents are incompatible.

447 records 18/30 page Previous Next First page 上5页 1617181920 下5页 Last page